Kyverna Therapeutics (KYTX) 8-K Summary

Kyverna Therapeutics has secured a non-dilutive term loan facility of up to $150.0 million.

• Financing Terms: Initial draw expected to be $25.0 million (Nov 3, 2025). Maturity is October 1, 2030.
• Security Interest: The Company granted a security interest in substantially all assets, including intellectual property.
• Clinical Guidance: The company now expects to report topline registrational data for its Phase 2 trial of KYV-101 for stiff person syndrome in early 2026.

This financing provides capital without